Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
- OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)1,2
- The agreement between both parties provides a framework to support the public listings and reimbursement of OFEV® for PF-ILD
BURLINGTON, ON, February 15, 2022 - Boehringer Ingelheim (Canada) Ltd. and the pan-Canadian Pharmaceutical Alliance (pCPA) have completed negotiations for OFEV® (nintedanib), a multi-targeted tyrosine kinase inhibitor for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD).1
"The successful conclusion of our negotiations with pCPA means that patients living with PF-ILD, which is a very debilitating condition, are one step closer to receiving treatment, to slow the progression of lung scarring," says Andrea Sambati, President and CEO of Boehringer Ingelheim (Canada) Ltd. "We look forward to working with jurisdictions across Canada to secure coverage from publicly funded drug plans, as there is no time to waste for these patients."
"This is encouraging news for the CPFF community across Canada,” says Sharon Lee, executive director of the Canadian Pulmonary Fibrosis Foundation (CPFF). “We hope that provinces move swiftly to add OFEV to their drug plans to improve access to much-needed care and treatment for PF-ILD patients, care that enables them to preserve lung function and spend more time with their loved ones.”
About OFEV®
OFEV® received authorization for sale for patients with PF-ILD by Health Canada in May 2020.1 OFEV®, a multi-targeted tyrosine kinase inhibitor that inhibits key pathways involved in lung fibrosis in ILDs, is also indicated for the treatment of idiopathic pulmonary fibrosis (IPF), and to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD (SSc-ILD) – two types of ILDs.1
About PF-ILD
Progressive fibrosing interstitial lung disease (PF-ILD) is a condition where a patient with interstitial lung disease (ILD) develops a ‘progressive fibrosing phenotype’ 2,3 leading to irreversible4,5,6 and progressive damage3,4,5 to both lung structure and function.4,5,6,7,8 People living with PF-ILD are severely impacted 9,10 as the disease is characterized by worsening of lung function and respiratory symptoms, reduced quality of life, and early mortality.11 Early diagnosis and treatment are essential for the best possible outcome for people with PF-ILD.12
About Boehringer Ingelheim (Canada) Ltd.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada. Learn more at www.boehringer-ingelheim.ca.
References
[1] Boehringer Ingelheim Canada (2022). Available at: https://www.boehringer-ingelheim.ca/en/press-release/ofev-nintedanib-now-available-canada-adults-living-progressive-fibrosing-interstitial
[2] Flaherty KR, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res 2017;4:e00021.
[3] Byrne A, Maher T, Lloyd C. Pulmonary Macrophages: A new therapeutic pathway in fibrosing lung disease? Trends Mol Med 2016;22:303–316.
[4] Leach H, et al. Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury. Am J Respir Cell Mol Biol 2013;49(6):1093–1101.
[5] Alunno A, et al. Clinical, epidemiological, and histopathological features of respiratory involvement in rheumatoid arthritis. Biomed Res Int 2017;7915340.
[6] Wynn T. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339–1350.
[7] Murtha L, et al. The processes and mechanisms of cardiac and pulmonary fibrosis. Front Pysiol 2017;8:777.
[8] Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 2013;304:C216–C225.
[9] Yasuoka H. Recent treatments of interstitial lung disease with systemic sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:97–110.
[10] Mittoo S, et al. Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). Curr Respir Med Rev 2015;11:175–183.
[11] Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018;27(150):pii:180076.
[12] Kolb M, Vasakova M (2019) The natural history of progressive fibrosing interstitial lung diseases. Respir Res 20 (1): 57.
Media Contacts
